BioLife (NASDAQ: BLFS) CFO RSU vesting triggers tax withholding

Rhea-AI Filing Summary

BioLife Solutions Inc. Chief Financial Officer Troy Wichterman had 844 shares of common stock withheld on April 8, 2026 to cover tax obligations from the release of restricted stock units. The shares were valued at $19.27 each, and he now directly holds 216,056 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wichterman Troy

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	844	$19.27	$16K

Holdings After Transaction: Common Stock — 216,056 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 844 shares Reported per-share value: $19.27 per share Shares held after transaction: 216,056 shares +2 more

5 metrics

Shares withheld for taxes 844 shares Withheld on April 8, 2026 to satisfy tax obligations

Reported per-share value $19.27 per share Value applied to the 844 withheld shares

Shares held after transaction 216,056 shares Direct common stock ownership after tax-withholding event

Tax-withholding disposition count 1 transaction Single F-code event reported in Form 4

Tax-withholding shares total 844 shares Total shares involved in F-code tax-withholding disposition

Key Terms

restricted stock units, tax withholding obligations, tax-withholding disposition, Form 4, +1 more

5 terms

restricted stock units financial

"arose upon the release of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy tax withholding obligations"

tax-withholding disposition financial

"transaction_action: "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Financial Officer financial

"officer_title": "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wichterman Troy

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WASHINGTON 98021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/08/2026		F		844	D	$19.27(1)	216,056	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Remarks:

	/s/ Troy Wichterman	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BioLife Solutions (BLFS) CFO report in this Form 4 filing?

The CFO reported that 844 shares of common stock were withheld by the company to satisfy his tax withholding obligations arising from the release of restricted stock units, rather than from any open-market stock sale or purchase.

Was the BLFS CFO’s Form 4 transaction an open-market sale of shares?

No, the filing shows a tax-withholding disposition. The company withheld 844 shares to pay taxes due on vested restricted stock units, meaning this was not a discretionary open-market sale by the executive.

How many BioLife Solutions shares does the CFO hold after this Form 4 event?

Following the tax-withholding event, the Form 4 reports that the CFO directly owns 216,056 shares of common stock. This figure reflects his position after the company withheld 844 shares to cover tax obligations tied to restricted stock units.

What price per share is reported in the BLFS CFO’s tax-withholding transaction?

The Form 4 lists a value of $19.27 per share for the 844 shares withheld. This price is used for reporting the tax-withholding disposition related to the release of the CFO’s restricted stock units, not an executed market trade.

Why were 844 BLFS shares withheld from the CFO’s holdings?

According to the footnote, BioLife Solutions withheld 844 shares to satisfy the CFO’s tax withholding obligations triggered when his restricted stock units were released, which is a common mechanism for covering income taxes on equity compensation.